Integra LifeSciences Corporation
The purpose of this registry is to collect real-world information on patients treated with Urinary Bladder Matrix (UBM) products. The study will evaluate patient characteristics, treatment patterns, and clinical outcomes to better understand how UBM products are used in routine clinical practice and the outcomes experienced by patients over time.
This is a multicenter, observational patient registry designed to collect real-world data on the use and performance of Urinary Bladder Matrix (UBM) products in wound care. The registry includes both retrospective and prospective patients treated with UBM products as part of routine clinical practice. Treatment decisions, including the use of UBM products, wound care interventions, adjunctive therapies, and follow-up, are determined by the treating clinician according to standard clinical practice. The registry does not require protocol-mandated treatments, study visits, procedures, or assess…
Inclusion Criteria * Adults aged ≥21 years at the time of initial urinary bladder matrix (UBM) product application. * Received or are receiving an eligible UBM product for treatment of a qualifying wound, including: Pressure ulcer (Stage III/IV) Necrotizing soft tissue infection (NSTI) Fournier's gangrene Pilonidal cyst Open abdomen Hidradenitis suppurativa Acute or chronic lower extremity wound Surgical incisional wound (retrospective cohort only) * For retrospective participants, medical records must contain sufficient source documentation to support data abstraction, including wound char…
Commercially available UBM wound management products used as part of routine clinical practice. Treatment selection, application frequency, and wound management approach are determined by the treating clinician and are not dictated by the registry protocol.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.